For decades, traumatic brain injury litigation has been fought on contested ground: a plaintiff describes debilitating symptoms, a defense expert points to a normal CT scan, and a jury is left to decide who is telling the truth. That dynamic is changing in 2026. The publication of the CBI-M (Clinical-Biomarker-Imaging-Modifiers) framework in Lancet Neurology in 2025, combined with FDA-cleared blood biomarker testing, has introduced a level of objective, standardized evidence into TBI assessment that courts and attorneys are only beginning to understand. For plaintiffs with real brain injuries and negative conventional imaging, this framework may be the most significant evidentiary development in a generation.
What Is the CBI-M Classification System and Why Does It Matter for TBI Cases?
The CBI-M classification system traumatic brain injury litigation settlement evidence framework reorganizes how clinicians — and now courts — define and prove brain injury severity. Rather than relying on a single data point like the Glasgow Coma Scale (GCS) score or a CT scan result, CBI-M integrates four distinct pillars into a unified severity classification:
- Clinical (C): Traditional markers including GCS score, loss of consciousness duration, post-traumatic amnesia, and presenting neurological symptoms.
- Biomarker (B): Blood-based proteins — primarily Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1), as well as S100B — that indicate measurable cellular brain tissue damage at the molecular level.
- Imaging (I): Structural abnormalities identified through CT and MRI, including advanced modalities such as diffusion tensor imaging (DTI) that can detect white matter tract disruption invisible to standard scans.
- Modifiers (M): Contextual factors that affect injury presentation and recovery trajectory, including patient age, pre-existing comorbidities, anticoagulant use, and the specific biomechanical mechanism of the injury.
According to the CDC’s traumatic brain injury data resource center, approximately 1.5 million Americans sustain a TBI annually, and mild TBI — the category most commonly disputed in litigation — accounts for the vast majority of those cases. The CBI-M framework was designed precisely to bring scientific rigor to the assessment of mild TBI, where symptom-only evaluation has historically left both clinicians and courts without reliable objective tools.
What makes this a genuine litigation game-changer is the “B” pillar. For the first time, a published, peer-reviewed, internationally recognized classification framework formally integrates blood biomarkers as a severity determinant — not as experimental findings, but as standard clinical evidence.
FDA-Cleared Blood Biomarkers: The Science Behind GFAP and UCH-L1
The biomarker pillar of the CBI-M classification system traumatic brain injury litigation settlement evidence framework rests on two proteins that have received FDA clearance for clinical use in TBI assessment. Understanding what these proteins do — and what their elevation proves — is essential for attorneys building damages cases in 2026.
GFAP: A Direct Marker of Brain Cell Injury
Glial Fibrillary Acidic Protein is a structural protein found exclusively in astrocytes, the support cells of the central nervous system. When brain tissue is damaged — even at a level too subtle for CT imaging to detect — astrocytes release GFAP into the bloodstream. Elevated GFAP levels in a blood sample drawn within 12 hours of a head injury provide direct, quantifiable evidence that brain cells have been physically disrupted. This is not a subjective symptom report. It is a measurable molecular signal of tissue injury.
UCH-L1: Neuronal Damage at the Cellular Level
Ubiquitin C-terminal Hydrolase L1 is a protein found predominantly in neurons. Its presence in elevated concentrations in peripheral blood following head trauma indicates neuronal cell body damage. Studies published between 2020 and 2024 demonstrate that GFAP combined with UCH-L1 achieves high sensitivity and high negative predictive value for detecting clinically relevant intracranial lesions — meaning these tests are exceptionally reliable at identifying real injury and ruling out injury in low-risk patients.
The FDA clearance of the combined GFAP/UCH-L1 assay specifically authorizes its use to aid in the evaluation of mild TBI and to identify patients who are unlikely to have intracranial lesions visible on CT. This dual function — confirming injury and safely triaging patients who can forgo CT radiation — represents a structural shift in emergency TBI evaluation that directly affects the evidentiary landscape of brain injury claims. For cases involving TBI from motor vehicle collisions, this objective evidence becomes particularly powerful when paired with a car accident settlement calculator analysis that factors measurable injury severity into compensation estimates.
Key Biomarker Performance Statistics
| Biomarker | Source Tissue | FDA Clearance Status (2026) | Primary Clinical Use | Key Performance Metric |
|---|---|---|---|---|
| GFAP | Astrocytes (CNS support cells) | FDA-cleared (combined assay) | Detect CT-visible intracranial lesions in mild TBI | High sensitivity for intracranial lesion detection |
| UCH-L1 | Neurons (cell bodies) | FDA-cleared (combined assay) | Detect neuronal damage; support CT triage decisions | High negative predictive value for intracranial injury |
| S100B | Glial cells / Schwann cells | Widely used clinically; European regulatory approval | Early TBI screening; severity stratification | Strong early-window sensitivity |
| GFAP + UCH-L1 Combined | Multi-tissue CNS origin | FDA-cleared combination panel | Aid CT decision-making; identify low-risk patients | Reduces unnecessary CT by identifying low-risk patients |
Sources: FDA device clearance database; peer-reviewed studies 2020–2024 cited in Lancet Neurology CBI-M framework publication (2025).
How CBI-M Changes the Litigation Battlefield in 2026
The CBI-M classification system traumatic brain injury litigation settlement evidence framework directly addresses the three most common defense strategies in TBI cases: the “no visible injury” argument, the symptom exaggeration argument, and the pre-existing condition argument. Here is how each pillar dismantles those defenses.
Defeating the “Normal CT” Defense
The single most damaging defense argument in mild TBI cases has historically been: “The CT scan was negative, so there is no objective evidence of brain injury.” The CBI-M framework makes this argument scientifically obsolete. When a plaintiff’s blood biomarkers — drawn in the emergency room hours after the accident — show elevated GFAP and UCH-L1 levels, those values document cellular brain tissue disruption regardless of what the CT reveals. The framework explicitly recognizes that CT-negative mild TBI can produce measurable biomarker elevation, correlating with real injury, real symptoms, and real functional consequences.
Defense experts who rely on CT negativity in 2026 are arguing against an FDA-cleared, published, peer-reviewed framework that major medical institutions are adopting as standard care. That is a significantly weaker position than it was even two years ago. Attorneys handling these cases can now pair biomarker evidence with severity-stratified damages models — tools like a personal injury settlement calculator that account for documented neurological injury rather than contested symptom accounts.
Replacing Symptom Debate with Molecular Evidence
Before the CBI-M era, TBI severity was largely adjudicated through competing expert opinions about the credibility and consistency of reported symptoms. Headaches, cognitive fog, sleep disruption, and emotional dysregulation are all real consequences of TBI — but they are also symptoms that defense teams routinely characterize as exaggerated, psychosomatic, or attributable to pre-existing mental health conditions. Biomarker evidence changes this calculus fundamentally.
When a plaintiff’s medical record includes a documented GFAP level measured within 12 hours of injury, that is a biological timestamp of brain cell damage. It does not rely on the plaintiff’s subjective experience. It does not depend on consistent symptom reporting over months. It is a laboratory value, drawn contemporaneously with the injury, that an expert witness can present to a jury with the same scientific authority as a broken bone on an X-ray. The CBI-M classification system traumatic brain injury litigation settlement evidence framework transforms this single data point into part of a multi-dimensional classification that a jury can follow and a court can apply to damages.
Quantifying the Modifiers Pillar for Damages Calculation
The “M” pillar — modifiers — has direct relevance to damages calculation that defense teams are only beginning to recognize. Age, comorbidities, and injury mechanism are not just background facts; under CBI-M, they are formal components of the severity assessment. An older plaintiff with a pre-existing hypertension diagnosis who sustains a rotational acceleration-deceleration injury in a commercial truck collision may have a modifiers profile that formally elevates their CBI-M severity classification compared to a younger, healthy plaintiff with identical biomarker and imaging findings. For attorneys handling cases involving large commercial carriers, understanding how CBI-M modifiers affect severity classification — and therefore damages — is now a core competency. Severity stratification under CBI-M can be especially consequential when paired with a truck accident calculator that accounts for aggravated injury profiles in high-force commercial vehicle collisions.
Practical Steps for Attorneys Using CBI-M Evidence in 2026
Understanding the science is only the first step. Translating the CBI-M classification system traumatic brain injury litigation settlement evidence framework into effective case strategy requires attention to timing, documentation, and expert selection.
Biomarker Testing Windows and Evidence Preservation
GFAP and UCH-L1 are most accurately measured within 12 hours of injury. S100B has an even narrower optimal window. This means that evidence preservation in TBI cases now begins in the emergency room — not in an attorney’s office weeks later. Attorneys should immediately obtain all emergency room blood work, request specific documentation of whether biomarker testing was performed, and if it was not performed, document why. In cases where biomarker testing was not conducted, the absence of testing does not mean the absence of injury; it means the contemporaneous objective evidence was never collected, which is itself a relevant fact.
Multi-Modal Imaging Beyond Standard CT
The imaging pillar of CBI-M supports the use of advanced MRI modalities that go beyond what emergency CT provides. Diffusion tensor imaging (DTI) can visualize white matter tract integrity with a specificity that standard T1/T2 MRI cannot approach. Susceptibility-weighted imaging (SWI) can detect microhemorrhages invisible on standard sequences. Attorneys building damages cases in 2026 should work with treating neurologists and neuroradiologists to ensure that all available imaging modalities have been utilized before the defense argues that “imaging is normal.” Under the CBI-M framework, multi-modal imaging failure to find abnormality is a far higher bar to clear than a single negative CT.
Expert Witness Qualification in the CBI-M Era
As the CBI-M framework achieves broader clinical adoption in 2026, courts will increasingly expect plaintiff experts to demonstrate familiarity with it. An expert who testifies about TBI severity without reference to CBI-M — particularly in cases where biomarker data is available — may face credibility challenges from defense counsel. Conversely, a plaintiff expert who can walk a jury through a CBI-M severity classification, explain the FDA clearance of GFAP/UCH-L1 testing, and anchor the plaintiff’s damages to a scientifically validated framework holds a substantial evidentiary advantage. For procedural standards on expert witness qualification in federal courts, Federal Rule of Evidence 702 continues to govern admissibility of expert testimony and has accommodated biomarker-based TBI evidence in recent years.
CBI-M, Damages Calculation, and the Path to Full Compensation
The ultimate litigation impact of the CBI-M classification system traumatic brain injury litigation settlement evidence framework is on damages. Severity classification drives damages in two ways: it establishes the biological reality of the injury at the liability stage, and it provides a structured framework for projecting future care needs, cognitive rehabilitation requirements, and lost earning capacity at the damages stage.
A plaintiff classified under CBI-M with elevated biomarkers, multi-modal imaging abnormalities, and significant modifiers has a documented clinical profile that supports claims for long-term neuropsychological treatment, vocational rehabilitation, and non-economic damages for reduced quality of life. This is not speculation — it is a severity classification derived from the same scientific framework used by treating clinicians. Courts applying established personal injury law principles to CBI-M-classified TBI cases will increasingly see plaintiffs able to present damages frameworks grounded in objective, standardized severity evidence rather than contested symptom narratives.
In the most severe cases where TBI results in death, the CBI-M classification system traumatic brain injury litigation settlement evidence record also strengthens wrongful death claims by documenting the severity of the neurological insult that ultimately proved fatal — providing a biological record of causation and severity that supports the full range of survivor damages.
Frequently Asked Questions About CBI-M and TBI Litigation
What is the CBI-M framework and how does it differ from traditional TBI classification systems?
The CBI-M (Clinical-Biomarker-Imaging-Modifiers) framework is a multi-dimensional TBI classification system published in Lancet Neurology in 2025 and entering clinical adoption in 2026. Unlike traditional systems that rely primarily on GCS scores or CT findings, CBI-M integrates four pillars: clinical presentation, blood-based biomarkers (GFAP, UCH-L1, S100B), structural and advanced imaging findings, and contextual modifiers like age and injury mechanism. The result is a comprehensive, standardized severity classification that reduces reliance on any single data point — especially for mild TBI cases where conventional imaging is frequently normal.
Are GFAP and UCH-L1 blood tests admissible as evidence in TBI lawsuits?
Yes. The GFAP/UCH-L1 combined assay has received FDA clearance for clinical use in TBI evaluation, which establishes it as an accepted diagnostic tool rather than experimental technology. Under Federal Rule of Evidence 702 and Daubert standards, FDA-cleared tests supported by peer-reviewed clinical validation studies meet the threshold for scientific reliability required for expert testimony. Attorneys should work with qualified neurologists or emergency medicine physicians who can explain the FDA clearance status, the scientific basis of the assay, and the clinical significance of a plaintiff’s specific biomarker values to a judge or jury.
What happens in TBI cases where biomarker testing was never performed at the emergency room?
The absence of biomarker testing does not defeat a TBI claim. Many emergency departments were not routinely performing GFAP/UCH-L1 testing prior to widespread CBI-M adoption, and implementation varies by facility in 2026. In cases where testing was not done, plaintiff attorneys should focus on the remaining CBI-M pillars — clinical documentation, advanced imaging, and modifiers — and present the absence of biomarker testing as a gap in the defendant’s ability to disprove injury rather than evidence that injury did not occur. Retaining a neuropsychologist to document persistent cognitive deficits remains a powerful supplement to biological evidence.
How does the CBI-M classification affect the calculation of TBI settlement amounts?
CBI-M classification directly supports damages calculation by providing objective, standardized evidence of injury severity that can anchor expert testimony on future care costs, vocational impact, and non-economic losses. A plaintiff with a higher CBI-M severity classification — supported by elevated biomarkers, imaging abnormalities, and adverse modifiers — has a documented clinical profile that justifies larger damages claims for long-term neuropsychological treatment, cognitive rehabilitation, reduced earning capacity, and pain and suffering. The framework transforms damages arguments from credibility contests about symptoms into evidence-based severity analyses that are harder for defense experts to dismiss.
Can the defense use CBI-M against plaintiffs who have normal biomarker levels after a TBI claim?
This is an important consideration. If biomarker testing was performed contemporaneously and results are within normal ranges, the defense may attempt to use that data to argue against the existence of significant intracranial injury. However, normal biomarker levels have a nuanced interpretation: they are strong evidence against CT-detectable intracranial lesions, but they do not rule out all forms of TBI-related functional impairment, particularly diffuse axonal injury at the microstructural level that biomarkers may not fully capture. Plaintiff attorneys in these situations should lean heavily on the imaging and clinical pillars of CBI-M, advanced neuroimaging modalities like DTI, and neuropsychological testing to establish the full injury picture.
This content is provided for educational and informational purposes only and does not constitute legal advice; consult a qualified attorney licensed in your jurisdiction for guidance specific to your case.
Robert Callahan is a TBI and Catastrophic Injury Researcher with extensive knowledge of personal injury law and settlement values across the United States. With years of experience analyzing brain injury / tbi claims only cases, Robert helps injury victims understand their legal rights and the potential value of their claims. Robert is not an attorney and the information provided is for educational purposes only.